{
    "clinical_study": {
        "@rank": "92400", 
        "acronym": "Fib-P-2011", 
        "arm_group": [
            {
                "arm_group_label": "NPS from yeast", 
                "arm_group_type": "Experimental", 
                "description": "Powder containing the active ingredients (500mg NPS from yeast) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks. 2 weeks before vaccination and 3 weeks after vaccination."
            }, 
            {
                "arm_group_label": "NPS from shiitake", 
                "arm_group_type": "Experimental", 
                "description": "Powder containing the active ingredient (500mg NPS from shitake) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination."
            }, 
            {
                "arm_group_label": "NPS from oat", 
                "arm_group_type": "Experimental", 
                "description": "Powder containing the active ingredient (10g NPS from oat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination."
            }, 
            {
                "arm_group_label": "NPS from wheat", 
                "arm_group_type": "Experimental", 
                "description": "Powder containing the active ingredient (10g NPS from wheat) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination."
            }, 
            {
                "arm_group_label": "NPS from Lactobacillus mucosae", 
                "arm_group_type": "Experimental", 
                "description": "Powder containing the active ingredient (2,3g NPS from L. mucosae) as well as filling substances (maltodextrins) and flavour adding up to 12.0 g altogether in sachets; consumed once daily after having been stirred in milk or filtered apple juice (ca. 200 ml/ 1 glass) for 5 weeks: 2 weeks before vaccination and 3 weeks after vaccination."
            }, 
            {
                "arm_group_label": "Maltodextrin", 
                "arm_group_type": "Placebo Comparator", 
                "description": "12.0 g Maltodextrin and flavour with identical/similar appearance and taste (when mixed in drink), consumed once daily as described for the active products (NPS."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to estimate the effect size of a 5-week consumption period of\n      different dietary non-digestible polysaccharides (NPS) on antibody response to influenza\n      vaccination and cellular immunity of healthy volunteers (aged \u2265 50) for clarifying whether\n      these NPS may enable enhancement of immune defence and to estimate the sample size for a\n      confirmative trial. Furthermore the effects on faecal microbiota and its metabolites will be\n      investigated."
        }, 
        "brief_title": "Pilot Study on Effect Size of Non-digestible Polysaccharides (NPS) on Immunity", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Immunosenescence", 
        "detailed_description": {
            "textblock": "The study is conducted in the frame of the collaborative project 'FibeBiotics' (Nr. 289517)\n      (Fibers as support of the Gut and Immune function of Elderly - From polysaccharide compound\n      to health claim) within the Seventh Framework Programme (FP7) for Research and Technological\n      Development of the European Union (EU)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Free-living postmenopausal woman and men aged \u2265 50 years willing to have influenza\n             vaccination season 2012/2013\n\n          -  willingness to abstain as far as possible from food and supplements containing\n             probiotics, prebiotic supplements, other fermented products, supplements containing\n             vitamins and minerals as well as willing to sustain on a low dietary fibre diet for 7\n             weeks.\n\n          -  written informed consent\n\n        Exclusion Criteria:\n\n          -  Subjects enrolled in another clinical study in the last 4 weeks\n\n          -  Subjects already vaccinated against influenza during 2012-2013 with either the\n             influenza vaccine used in the present study or another influenza vaccine\n\n          -  vaccination against influenza within the previous 10 months\n\n          -  suffering from influenza or influenza-like illness within the previous 10 months\n\n          -  other vaccinations during and within 2 months before the study\n\n          -  symptoms of common infectious diseases (CID) of the airways or other organ systems\n             e.g. gastrointestinal tract in the last 4 weeks before inclusion\n\n          -  known congenital, acquired or iatrogenic immunodeficiency (e.g. HIV, chemotherapy,\n             immunosuppression)\n\n          -  active autoimmune diseases\n\n          -  allergy or hypersensitivity to any component of the vaccine (e. g. chicken egg\n             protein, certain antibiotics)(s. a. 9.2)\n\n          -  allergy or hypersensitivity to any component of the test product (e. g. yeast,\n             gluten, shiitake mushrooms)\n\n          -  allergy to latex\n\n          -  known coeliac disease (gluten enteropathy)\n\n          -  bowel movement less than 3 times per week\n\n          -  subjects, who meet 2 or more Rome III criteria for constipation or who take laxatives\n             on a regular basis\n\n          -  severe chronic disease (cancer, IBD, malabsorption, malnutrition, chronic\n             inflammatory diseases, renal, hepatic or cardiac diseases, COPD, respiratory\n             insufficiency)\n\n          -  chronic abdominal pain\n\n          -  malformation of fingers\n\n          -  systemic treatment or topical treatment likely to interfere with evaluation of the\n             study parameters: antibiotics, intestinal or respiratory antiseptics,\n             anti-rheumatics, antiphlogistics (except aspirin or equivalent products preventing\n             from aggregation of platelets or blood clotting) and steroids prescribed in chronic\n             inflammatory diseases\n\n          -  other treatments likely to interfere with study outcome (e.g. laxatives, body weight\n             management and/or medication)\n\n          -  treatments with calcium antagonists and nitrates and alpha blockers\n\n          -  diabetes mellitus on drug therapy\n\n          -  severe neurological, cognitive or psychiatric diseases\n\n          -  surgery or intervention requiring general anaesthesia within 2 months before the\n             study\n\n          -  vegetarian, vegan\n\n          -  eating disorders  (e.g. anorexia, bulimia)\n\n          -  alcohol and drug abuse\n\n          -  pregnancy or lactation\n\n          -  legal incapacity\n\n          -  blood parameters: Hb < 12 g/dL Liver transaminases (ALT, AST)  > 2-fold increased\n             Serum creatinine > 1,2 mg/dL"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896154", 
            "org_study_id": "Fib-P-2011"
        }, 
        "intervention": {
            "arm_group_label": [
                "NPS from yeast", 
                "NPS from shiitake", 
                "NPS from oat", 
                "NPS from wheat", 
                "NPS from Lactobacillus mucosae"
            ], 
            "description": "Comparison of multiple dietary non-digestible polysaccharides", 
            "intervention_name": "NPS", 
            "intervention_type": "Dietary Supplement"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "non-digestible polysaccharides,influenza vaccination, HI titres", 
        "lastchanged_date": "July 8, 2013", 
        "number_of_arms": "6", 
        "official_title": "A Randomized, Controlled Clinical Study on the Effect of Non-digestible Polysaccharides (NPS) on the Immune Response to Influenza Vaccination in Elderly", 
        "overall_official": [
            {
                "affiliation": "Clinical Research Center Kiel GmbH", 
                "last_name": "Christiane Laue, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Gutenberg University Mainz", 
                "last_name": "Juergen Schrezenmeir, MD, PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethics Commission", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Geometric mean titre of antibodies against one of the 3 influenza strains in HI test", 
            "safety_issue": "No", 
            "time_frame": "3 weeks after vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896154"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Clinical Research Center Kiel GmbH", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "European Commission", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Food & Biobased Research - Wageningen UR", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Teagasc Agriculture Food and Development Authority", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Nofima AS", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "BioActor B.V.", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Swedish Oat Fiber AB", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Immitec", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Institut Pasteur", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "University of Bologna", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Clinical Research Center Kiel GmbH", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}